Facts and Hopes in Thrombolysis in Acute Myocardial Infarction
暂无分享,去创建一个
[1] P. Walker,et al. Induction of a sustained fibrinolytic response by BRL 26921 in vitro. , 1985, Thrombosis research.
[2] C. Francis,et al. Relationship of the lytic state to successful reperfusion with standard- and low-dose intracoronary streptokinase. , 1985, Circulation.
[3] J. Hoffmann,et al. Systemic effects of BRL 26921 during thrombolytic treatment of acute myocardial infarction. , 1985, Thrombosis research.
[4] R. Hornung,et al. Coronary thrombolysis with intravenous anisoylated plasminogen-streptokinase complex BRL 26921. , 1985, British heart journal.
[5] R. Erbel,et al. Intracoronary thrombolysis with an acylated streptokinase-plasminogen activator (BRL 26921) in patients with acute myocardial infarction. , 1984, Journal of the American College of Cardiology.
[6] R. Smith,et al. Acyl-Enzymes as Thrombolytic Agents in Dog Models of Venous Thrombosis and Pulmonary Embolism , 1984, Thrombosis and Haemostasis.
[7] A. Rae,et al. Acylated Streptokinase – Plasminogen Complex in Patients with Acute Myocardial Infarction , 1984, Thrombosis and Haemostasis.
[8] M. Verstraete,et al. On the fibrinolytic and thrombolytic properties of active-site p-anisoylated streptokinase-plasminogen complex (BRL 26921). , 1981, Thrombosis research.
[9] R. Smith,et al. Fibrinolysis with acyl-enzymes: a new approach to thrombolytic therapy , 1981, Nature.
[10] R. Norris,et al. A new coronary prognostic index. , 1970, Lancet.
[11] J. Mills,et al. Proceedings of the British Cardiac Society Acute coronary thrombolysis with a single intracoronary injection of BRL 26921 , 2022 .